Wu Yanqin相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Menstrual blood-derived stem cell exosomes improve ovarian function in chemotherapy-Induced POF rats via apoptosis regulation

月经血来源的干细胞外泌体通过调节细胞凋亡改善化疗诱导的卵巢早衰（POF）大鼠的卵巢功能。

期刊:Scientific Reports

影响因子:3.9

doi:10.1038/s41598-026-43562-0

Cheng, Xianying; Wu, Yanqin; Cheng, Li; Liu, Minjie; Gan, Kwanghann; Wang, Yuanyuan; Zhang, Ting; Yang, Lingqiao; Wang, Yige; Xu, Liya; Xu, Zhenyu

细胞生物学

发育与干细胞

发表日期：2026

文献求助收藏

Transcriptomic insights into the immunological similarities and differences among the spleen, head kidney, and trunk kidney in Hemibarbus Labeo

通过转录组学分析揭示了半鲃鱼脾脏、头肾和躯干肾在免疫学上的异同

期刊:BMC Genomics

影响因子:3.7

doi:10.1186/s12864-026-12603-3

Lv, Yaoping; Zhu, Ling; Gao, Xinming; Dai, Qingmin; Hu, Zehui; Lu, Junkai; Tu, Jianhui; Zhao, Yang; Wu, Yanqin

免疫/内分泌

发表日期：2026

文献求助收藏

The miR-34/449 clusters regulate the differentiation of ciliated cells in the oviduct via the Wnt/β-catenin signaling pathway

miR-34/449簇通过Wnt/β-catenin信号通路调控输卵管纤毛细胞的分化。

期刊:Cell and Bioscience

影响因子:6.1

doi:10.1186/s13578-025-01468-w

Qiqian Wu,Yunxia Zhang,Furong Bai,Yujie Wu,Yanqin Hu,Jingwen Wu

细胞生物学

发表日期：2025

文献求助收藏

Efficacy and safety of TACE combined with lenvatinib and PD-1 Inhibitor in intermediate-stage HCC exceeding the up-7 criteria: a retrospective cohort study

TACE联合乐伐替尼和PD-1抑制剂治疗超过UP-7标准的中晚期肝细胞癌的疗效和安全性：一项回顾性队列研究

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2025.1560750

Xue, Miao; Wu, Yanqin; Tang, Yiyang; Huang, Kun; Liu, Haikuan; Zhu, Bowen; Wen, Jie; Zhao, Yue; Zhang, Guixiong; Liu, Hang; Fan, Wenzhe; Li, Jiaping

细胞生物学

发表日期：2025

文献求助收藏

UBE2N as a novel prognostic and therapeutic biomarker of lung adenocarcinoma.

UBE2N 作为肺腺癌的新型预后和治疗生物标志物

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2025.1636503

Yin Haofeng, Xue Yibo, Wang Chen, Wu Yanqin, Guo Yuchen, Li Chunzhen, Zhang Yunyan, Yin Shulei, Zhao Tiejun

发表日期：2025

文献求助收藏

Prediction Model of Survival in Unresectable HCC with Central Bile Duct Invasion Receiving TACE After Biliary Drainage: TEMP Score

不可切除的伴中央胆管侵犯的肝细胞癌患者接受胆道引流后行经导管动脉化疗栓塞术（TACE）的生存预测模型：TEMP评分

期刊:Journal of Hepatocellular Carcinoma

影响因子:3.4

doi:10.2147/JHC.S505328

Fan, Wenzhe; Zheng, Xinlin; Zhang, Weihong; Zhu, Bowen; Wu, Yanqin; Xue, Miao; Tang, Rong; Huang, Zhen; Qiao, Liangliang; Lu, Mingjian; Wu, Jian; Tang, Yiyang; Chen, Jinghua; Huang, Shugui; Bai, Mingjun; Li, Jiaping

细胞生物学

发表日期：2025

文献求助收藏

Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study

PD-1/PD-L1抑制剂治疗复发性胆管癌的疗效和安全性：一项真实世界、多中心回顾性研究

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-025-14459-4

Lin, Lihui; Lin, Yansong; Chen, Wei; Yang, Xia; Guo, Xianwen; Wu, Yanqin; Yin, Xiaoyu; Ding, Zhen; Yun, Jingping

发表日期：2025

文献求助收藏

Research trends in essential thrombocythemia from 2001 to 2024: a bibliometric analysis

2001年至2024年原发性血小板增多症研究趋势：文献计量分析

期刊:Discover Oncology

影响因子:2.9

doi:10.1007/s12672-025-02232-9

Pan, Yiming; Chen, Lingyan; Jiang, Qun; Chen, Dejian; Wu, Yanqin; Hou, Li; Lang, Haiyan; Yan, Jun

发表日期：2025

文献求助收藏

Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial

复发性中晚期肝细胞癌患者的生存率：索拉非尼联合TACE与单纯TACE随机临床试验

期刊:Jama Oncology

影响因子:20.1

doi:10.1001/jamaoncol.2024.1831

Fan, Wenzhe; Zhu, Bowen; Chen, Shuling; Wu, Yanqin; Zhao, Xiao; Qiao, Liangliang; Huang, Zhen; Tang, Rong; Chen, Jinghua; Lau, Wan Yee; Chen, Minshan; Li, Jiaping; Kuang, Ming; Peng, Zhenwei

细胞生物学

发表日期：2024

文献求助收藏

DEB-TACE versus cTACE for unresectable HCC with B1-type bile duct invasion after successful biliary drainage: A propensity score matching analysis

DEB-TACE 与 cTACE 治疗胆道引流成功后伴有 B1 型胆管侵犯的不可切除肝细胞癌：倾向评分匹配分析

期刊:Cancer Medicine

影响因子:3.1

doi:10.1002/cam4.7419

Fan, Wenzhe; Zheng, Xinlin; Zhao, Xiao; Zhu, Bowen; Wu, Yanqin; Xue, Miao; Tang, Rong; Huang, Zhen; Qiao, Liangliang; Lu, Mingjian; Tang, Yiyang; Wu, Jian; Li, Jiaping

细胞生物学

发表日期：2024

文献求助收藏